Latest Novo Holdings A/S Stock Portfolio
$1.45Billion– No. of Holdings #35
Novo Holdings A/S Performance:
2024 Q1: -8.79%YTD: -8.79%2023: 35.77%
Performance for 2024 Q1 is -8.79%, and YTD is -8.79%, and 2023 is 35.77%.
About Novo Holdings A/S and 13F Hedge Fund Stock Holdings
In it's latest 13F Holdings report, Novo Holdings A/S reported an equity portfolio of $1.4 Billions as of 31 Mar, 2024.
The top stock holdings of Novo Holdings A/S are ASML, , CRM. The fund has invested 12.2% of it's portfolio in ASML HOLDING N V and 11.2% of portfolio in BROOKFIELD CORP.
The fund managers got completely rid off TAIWAN SEMICONDUCTOR MFG LTD (TSM), EDGEWISE THERAPEUTICS INC (EWTX) and CYMABAY THERAPEUTICS INC (CBAY) stocks. They significantly reduced their stock positions in PHARVARIS N V (PHVS), APPLE INC (AAPL) and IO BIOTECH INC (IOBT). Novo Holdings A/S opened new stock positions in EDGEWISE THERAPEUTICS INC (EPC), VIRIDIAN THERAPEUTICS INC (VRDN) and ARRIVENT BIOPHARMA INC. The fund showed a lot of confidence in some stocks as they added substantially to LEXEO THERAPEUTICS INC.
The top stock holdings of Novo Holdings A/S are ASML, , CRM. The fund has invested 12.2% of it's portfolio in ASML HOLDING N V and 11.2% of portfolio in BROOKFIELD CORP.
The fund managers got completely rid off TAIWAN SEMICONDUCTOR MFG LTD (TSM), EDGEWISE THERAPEUTICS INC (EWTX) and CYMABAY THERAPEUTICS INC (CBAY) stocks. They significantly reduced their stock positions in PHARVARIS N V (PHVS), APPLE INC (AAPL) and IO BIOTECH INC (IOBT). Novo Holdings A/S opened new stock positions in EDGEWISE THERAPEUTICS INC (EPC), VIRIDIAN THERAPEUTICS INC (VRDN) and ARRIVENT BIOPHARMA INC. The fund showed a lot of confidence in some stocks as they added substantially to LEXEO THERAPEUTICS INC.
Novo Holdings A/S Equity Portfolio Value
Last Reported on: 15 May, 2024
Novo Holdings A/S Annual Return Estimates Vs S&P 500
Our best estimate is that Novo Holdings A/S made a return of -8.79% in the last quarter. In trailing 12 months, it's portfolio return was 9.31%.
New Buys
| Ticker | $ Bought |
|---|---|
| edgewise therapeutics inc | 115,722,000 |
| viridian therapeutics inc | 19,261,000 |
| arrivent biopharma inc | 19,237,700 |
| metagenomi inc | 18,348,300 |
| kyverna therapeutics inc | 17,388,000 |
New stocks bought by Novo Holdings A/S
Additions
| Ticker | % Inc. |
|---|---|
| lexeo therapeutics inc | 25.27 |
Additions to existing portfolio by Novo Holdings A/S
Reductions
| Ticker | % Reduced |
|---|---|
| pharvaris n v | -24.12 |
| apple inc | -17.38 |
| io biotech inc | -11.46 |
| salesforce inc | -9.49 |
| asml holding n v | -7.7 |
| 4d molecular therapeutics in | -6.67 |
| blueprint medicines corp | -0.14 |
| crinetics pharmaceuticals in | -0.13 |
Novo Holdings A/S reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| spruce biosciences inc | -19,696,400 |
| edgewise therapeutics inc | -66,424,400 |
| lava therapeutics nv | -2,967,550 |
| rallybio corp | -4,225,190 |
| cymabay therapeutics inc | -21,258,000 |
| taiwan semiconductor mfg ltd | -73,921,100 |
Novo Holdings A/S got rid off the above stocks
Sector Distribution
Novo Holdings A/S has about 40.5% of it's holdings in Others sector.
| Sector | % |
|---|---|
| Others | 40.5 |
| Healthcare | 35.8 |
| Technology | 12.3 |
| Consumer Defensive | 8 |
| Communication Services | 3.5 |
Market Cap. Distribution
Novo Holdings A/S has about 16% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| UNALLOCATED | 40.5 |
| MID-CAP | 23.2 |
| SMALL-CAP | 19.4 |
| MEGA-CAP | 12.1 |
| LARGE-CAP | 3.9 |
Stocks belong to which Index?
About 50% of the stocks held by Novo Holdings A/S either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| Others | 50 |
| RUSSELL 2000 | 37.9 |
| S&P 500 | 12.1 |
Novo Holdings A/S Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Novo Holdings A/S
Novo Holdings A/S has 35 stocks in it's portfolio. About 63% of the portfolio is in top 10 stocks. SPRO proved to be the most loss making stock for the portfolio. CRM was the most profitable stock for Novo Holdings A/S last quarter.
Last Reported on: 15 May, 2024| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| AAPL | apple inc | 2.16 | 182,960 | 31,374,000 | reduced | -17.38 | ||
| ABCL | abcellera biologics inc | 0.35 | 1,126,920 | 5,104,920 | unchanged | 0.00 | ||
| ALNY | alnylam pharmaceuticals inc | 1.22 | 118,383 | 17,692,300 | unchanged | 0.00 | ||
| ASML | asml holding n v | 12.22 | 182,536 | 177,146,000 | reduced | -7.7 | ||
| BABA | alibaba group hldg ltd | 2.50 | 500,827 | 36,239,800 | unchanged | 0.00 | ||
| BAM | brookfield asset managmt ltd | 1.82 | 627,207 | 26,355,200 | unchanged | 0.00 | ||
| BMRN | biomarin pharmaceutical inc | 2.71 | 450,000 | 39,303,000 | unchanged | 0.00 | ||
| BPMC | blueprint medicines corp | 2.35 | 358,626 | 34,019,300 | reduced | -0.14 | ||
| CABO | cable one inc | 3.46 | 118,403 | 50,099,900 | unchanged | 0.00 | ||
| CBAY | cymabay therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| CORT | corcept therapeutics inc | 4.19 | 2,411,360 | 60,742,200 | unchanged | 0.00 | ||
| CRM | salesforce inc | 9.98 | 480,160 | 144,615,000 | reduced | -9.49 | ||
| CRNX | crinetics pharmaceuticals in | 3.55 | 1,098,600 | 51,425,500 | reduced | -0.13 | ||
| EPC | edgewise therapeutics inc | 7.98 | 6,344,430 | 115,722,000 | new | |||
| EWTX | edgewise therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| FDMT | 4d molecular therapeutics in | 3.08 | 1,400,000 | 44,604,000 | reduced | -6.67 | ||
| FOLD | amicus therapeutics inc | 2.03 | 2,500,000 | 29,450,000 | unchanged | 0.00 | ||
| GLTO | galecto inc | 0.13 | 2,497,790 | 1,948,280 | unchanged | 0.00 | ||
| INSM | insmed inc | 2.51 | 1,339,300 | 36,335,300 | unchanged | 0.00 | ||
| INSP | inspire med sys inc | 0.97 | 65,524 | 14,073,900 | unchanged | 0.00 | ||